Published in Tob Control on December 01, 2003
The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control (2009) 3.10
The Tobacco Control Scale: a new scale to measure country activity. Tob Control (2006) 3.10
Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control (2006) 3.00
Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results? Tob Control (2009) 2.36
Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol (2007) 2.30
Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Reduct J (2006) 2.18
Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med (2007) 2.10
Is "YouTube" telling or selling you something? Tobacco content on the YouTube video-sharing website. Tob Control (2007) 2.06
A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J (2013) 1.93
Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health (2006) 1.80
Receptivity to Taboka and Camel Snus in a U.S. test market. Nicotine Tob Res (2009) 1.79
Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol (2010) 1.75
Non-cigarette tobacco products: what have we learnt and where are we headed? Tob Control (2012) 1.58
Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. Tob Control (2015) 1.55
Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts? Tob Control (2003) 1.52
Toward a comprehensive long term nicotine policy. Tob Control (2005) 1.52
Prevalence of trial of snus products among adult smokers. Am J Public Health (2011) 1.50
You might as well smoke; the misleading and harmful public message about smokeless tobacco. BMC Public Health (2005) 1.48
Cigarettes and oral snuff use in Sweden: Prevalence and transitions. Addiction (2006) 1.48
Is low-nicotine Marlboro snus really snus? Harm Reduct J (2008) 1.40
"Not safe" is not enough: smokers have a right to know more than there is no safe tobacco product. Tob Control (2005) 1.39
Smokeless tobacco use 1992-2002: trends and measurement in the Current Population Survey-Tobacco Use Supplements. Tob Control (2006) 1.38
Electronic cigarettes have a potential for huge public health benefit. BMC Med (2014) 1.35
The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer (2004) 1.34
Changing patterns of tobacco use in a middle-aged population: the role of snus, gender, age, and education. Glob Health Action (2011) 1.29
Perceptions of relative risk of snus and cigarettes among US smokers. Am J Public Health (2013) 1.25
Trends in beliefs about the harmfulness and use of stop-smoking medications and smokeless tobacco products among cigarettes smokers: Findings from the ITC four-country survey. Harm Reduct J (2011) 1.24
Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Tobacco use harm reduction, elimination, and escalation in a large military cohort. Am J Public Health (2010) 1.22
Transnational tobacco company interests in smokeless tobacco in Europe: analysis of internal industry documents and contemporary industry materials. PLoS Med (2013) 1.22
Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? Int J Environ Res Public Health (2008) 1.18
Developing the science base for reducing tobacco harm. Nicotine Tob Res (2007) 1.15
Tobacco harm reduction: what do the experts think? Tob Control (2004) 1.15
Smokeless tobacco brand switching: a means to reduce toxicant exposure? Drug Alcohol Depend (2006) 1.12
Impact of differing definitions of dual tobacco use: implications for studying dual use and a call for operational definitions. Nicotine Tob Res (2011) 1.11
The tobacco use management system: analyzing tobacco control from a systems perspective. Am J Public Health (2010) 1.11
Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States. BMC Oral Health (2008) 1.03
Patterns and behaviors of snus consumption in Sweden. Nicotine Tob Res (2009) 1.03
Harm perception among Swedish daily smokers regarding nicotine, NRT-products and Swedish Snus. Tob Induc Dis (2010) 1.02
The STAGE cohort: a prospective study of tobacco use among Swedish twins. Nicotine Tob Res (2008) 1.02
Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res (2009) 1.02
Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob Res (2012) 1.01
A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit. Nicotine Tob Res (2010) 1.00
Young Adults' Risk Perceptions of Various Tobacco Products Relative to Cigarettes: Results From the National Young Adult Health Survey. Health Educ Behav (2015) 1.00
Socio-demographic, lifestyle and health characteristics among snus users and dual tobacco users in Stockholm County, Sweden. BMC Public Health (2010) 0.98
Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch. Nicotine Tob Res (2014) 0.96
Snus use and other correlates of smoking cessation in the Swedish Twin Registry. Psychol Med (2008) 0.95
Genetics and smoking. Curr Addict Rep (2014) 0.95
What potential has tobacco control for reducing health inequalities? The New Zealand situation. Int J Equity Health (2006) 0.95
Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation. Harm Reduct J (2011) 0.94
Association between willingness to use snus to quit smoking and perception of relative risk between snus and cigarettes. Nicotine Tob Res (2012) 0.94
Risk perceptions of smokeless tobacco among adolescent and adult users and nonusers. J Health Commun (2015) 0.92
Tobacco Chewing and Associated Factors Among Youth of Western Nepal: A Cross-sectional Study. Indian J Community Med (2011) 0.91
Estimating demand for alternatives to cigarettes with online purchase tasks. Am J Health Behav (2014) 0.91
Influence of smoking and snuff cessation on risk of preterm birth. Eur J Epidemiol (2012) 0.89
Understanding the emergence of the tobacco industry's use of the term tobacco harm reduction in order to inform public health policy. Tob Control (2014) 0.89
Nicotine replacement therapy, professional therapy, snuff use and tobacco smoking: a study of smoking cessation strategies in southern Sweden. Tob Control (2007) 0.89
Smoker interest in lower harm alternatives to cigarettes: national survey data. Nicotine Tob Res (2009) 0.86
Is there any association between use of smokeless tobacco products and coronary heart disease in Bangladesh? PLoS One (2012) 0.86
A content analysis of smokeless tobacco coverage in U.S. newspapers and news wires. Nicotine Tob Res (2013) 0.86
Adolescent snus use in Finland in 1981-2003: trend, total sales ban and acquisition. Tob Control (2006) 0.86
Interviews with smokers about smokeless tobacco products, risk messages and news articles. Tob Control (2015) 0.86
Association between a 15q25 gene variant, nicotine-related habits, lung cancer and COPD among 56,307 individuals from the HUNT study in Norway. Eur J Hum Genet (2013) 0.85
Effects of a Fact Sheet on beliefs about the harmfulness of alternative nicotine delivery systems compared with cigarettes. Harm Reduct J (2012) 0.83
Mortality attributable to tobacco among men in Sweden and other European countries: an analysis of data in a WHO report. Tob Induc Dis (2014) 0.83
Some practical points on harm reduction: what to tell your lawmaker and what to tell your brother about Swedish snus. Tob Control (2003) 0.83
Intention to switch to smokeless tobacco use among South African smokers: results from the 2007 South African Social Attitudes Survey. PLoS One (2014) 0.83
Toxicity of gutkha, a smokeless tobacco product gone global: is there more to the toxicity than nicotine? Int J Environ Res Public Health (2014) 0.82
The most important and influential papers in tobacco control: results of an online poll. Tob Control (2005) 0.81
High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus. Tob Control (2014) 0.81
Introducing oral tobacco for tobacco harm reduction: what are the main obstacles? Harm Reduct J (2007) 0.79
Smokeless Tobacco Risk Comparison and Other Debate Messages in the News. Health Behav Policy Rev (2014) 0.79
Nicotine percentage replacement among smokeless tobacco users with nicotine patch. Drug Alcohol Depend (2007) 0.79
Snus undermines quit attempts but not abstinence: a randomised clinical trial among US smokers. Tob Control (2016) 0.79
The effect of oral uptake of nicotine in snus on peripheral skin blood circulation evaluated by thermography. Temperature (Austin) (2014) 0.78
Use of snus, its association with smoking and alcohol consumption, and related attitudes among adolescents: the Finnish National School Health Promotion Study. Tob Induc Dis (2015) 0.78
Public health measures to reduce smoking prevalence in the UK: how many lives could be saved? Tob Control (2005) 0.78
The impact of free trial acceptance on demand for alternative nicotine products: evidence from experimental auctions. Harm Reduct J (2015) 0.77
Tobacco use and associated factors among Adults in Uganda: Findings from a nationwide survey. Tob Induc Dis (2016) 0.77
Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction. BMC Med (2009) 0.77
Permissive nicotine regulation as a complement to traditional tobacco control. BMC Public Health (2005) 0.77
Surveillance indicators for potential reduced exposure products (PREPs): developing survey items to measure awareness. Harm Reduct J (2009) 0.76
Sweden SimSmoke: the effect of tobacco control policies on smoking and snus prevalence and attributable deaths. Eur J Public Health (2013) 0.76
Providing a Science Base for the Evaluation of Tobacco Products. Tob Regul Sci (2015) 0.76
Assessing Constituent Levels in Smokeless Tobacco Products: A New Approach to Engaging and Educating the Public. Nicotine Tob Res (2015) 0.75
Application of the Smokeless Tobacco Expectancies Questionnaire to Snus. Am J Health Behav (2016) 0.75
Flaw in WHO Framework Convention on Tobacco Control: letter identified wrong problem with the framework convention. BMJ (2004) 0.75
Naturalistic assessment of demand for cigarettes, snus, and nicotine gum. Psychopharmacology (Berl) (2016) 0.75
The effect of Swedish snuff (snus) on offspring birthweight: a sibling analysis. PLoS One (2013) 0.75
Much more than cigarette smoking. J Bras Pneumol (2014) 0.75
The tobacco-using periodontal patient: role of the dental practitioner in tobacco cessation and periodontal disease management. Periodontol 2000 (2016) 0.75
Ethical considerations of e-cigarette use for tobacco harm reduction. Respir Res (2016) 0.75
Putting tobacco harm reduction in perspective: is it a viable alternative? Indian J Med Res (2016) 0.75
Chemical and toxicological characteristics of conventional and low-TSNA moist snuff tobacco products. Toxicol Lett (2016) 0.75
Maternal snuff use and smoking and the risk of oral cleft malformations--a population-based cohort study. PLoS One (2014) 0.75
Gene expression profiles associated with cigarette smoking and moist snuff consumption. BMC Genomics (2017) 0.75
The changing tobacco landscape: What dental professionals need to know. J Am Dent Assoc (2016) 0.75
Impact of smoking on speed and coordination of upper limb movement. Addict Health (2015) 0.75
A qualitative study of smokers' responses to messages discouraging dual tobacco product use. Health Educ Res (2014) 0.75
Other tobacco product and electronic cigarette use among homeless cigarette smokers. Addict Behav (2016) 0.75
European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control (2003) 4.09
Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? Tob Control (2001) 3.91
Health effects associated with smokeless tobacco: a systematic review. Thorax (2003) 3.71
Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med (2003) 3.05
Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry (2001) 2.92
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol (2002) 2.43
Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health (1994) 2.41
Impact of smokeless tobacco use on smoking in northern Sweden. J Intern Med (2002) 2.37
Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol (1999) 2.29
Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national US sample. Addiction (2003) 2.26
Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol (1993) 2.02
Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer (1998) 2.02
Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ (1992) 2.00
Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst (1995) 1.92
Smokeless tobacco and cardiovascular disease. Prog Cardiovasc Dis (2003) 1.78
Evolving patterns of tobacco use in northern Sweden. J Intern Med (2003) 1.78
Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology (Berl) (1992) 1.73
Attack rate, mortality and case fatality for acute myocardial infarction in Sweden during 1987-95. Results from the national AMI register in Sweden. J Intern Med (2000) 1.61
Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control (1999) 1.58
Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke (2003) 1.48
Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med (2000) 1.45
A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) (2000) 1.42
Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. Am J Hypertens (1998) 1.36
Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer (1999) 1.33
Nasal nicotine solution: a potential aid to giving up smoking? Br Med J (Clin Res Ed) (1983) 1.25
Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med (1994) 1.24
The Swedish snus and the Sudanese toombak: are they different? Oral Oncol (1998) 1.22
Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey. J Intern Med (1992) 1.21
A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol (1998) 1.21
Between harm and dangers. Oral snuff use, cigarette smoking and problem behaviours in a survey of Swedish male adolescents. Eur J Public Health (2001) 1.15
Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction (2001) 1.15
Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis (1995) 1.12
Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis (1997) 1.12
Chemical profile of two types of oral snuff tobacco. Food Chem Toxicol (2002) 1.07
Long-term use of smokeless tobacco and physical performance in middle-aged men. Eur J Clin Invest (1997) 1.02
Unusually high levels of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak). Carcinogenesis (1991) 0.99
Mutagen levels in urine from snuff users, cigarette smokers and non tobacco users--a comparison. Mutat Res (1987) 0.95
Clearing the smoke or muddying the water? Tob Control (2001) 0.95
Tobacco habits among teenagers in the city of Göteborg, Sweden, and possible association with dental caries. Swed Dent J (1991) 0.90
Snuff, nicotine and cardiovascular disease: implications for tobacco control. J Am Coll Cardiol (1999) 0.90
Snuff use and smoking among senior high school students: effects of a snuff sales ban. Oral Dis (1998) 0.89
Volatile N-nitrosamines in snuff and chewing tobacco on the Swedish market. Food Chem Toxicol (1983) 0.88
Women in medicine: practice patterns and attitudes. CMAJ (1990) 4.27
European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control (2003) 4.09
Side effects of extinction procedures in a remedial preschool. J Appl Behav Anal (1972) 3.39
Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol (1988) 3.21
Two related recombinases are required for site-specific recombination at dif and cer in E. coli K12. Cell (1993) 2.78
Antipsychotic drug-induced dysphoria. Br J Psychiatry (1995) 2.77
Escherichia coli XerC recombinase is required for chromosomal segregation at cell division. New Biol (1991) 2.44
Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. Br J Surg (1994) 2.26
Antibiotic prophylaxis in dentistry: part I. A qualitative study of professionals' views on the NICE guideline. Br Dent J (2011) 2.24
Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology (1988) 2.20
Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2006) 2.04
Purpura associated with vomiting in pregnancy. Br Med J (1973) 1.98
Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry (1992) 1.80
Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev (2007) 1.71
Transposon-specified, site-specific recombination systems. Cold Spring Harb Symp Quant Biol (1981) 1.62
Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. Eur Heart J (2000) 1.59
Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet (1995) 1.55
Wire-guided balloon coloplasty--a new treatment for colorectal strictures? J R Soc Med (1991) 1.51
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS (2001) 1.48
Treatment of clozapine sedation. Am J Psychiatry (1993) 1.47
Primary biliary cirrhosis associated with antiphospholipid syndrome. Isr J Med Sci (1997) 1.45
Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med (2000) 1.44
Doppler sonography of the inferior mesenteric artery: a preliminary study. J Ultrasound Med (1995) 1.43
Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technol Assess (2004) 1.41
High-dose intravenous magnesium attenuates complement consumption after acute myocardial infarction treated by streptokinase. Eur Heart J (1996) 1.40
Bureaucratic logic in new social movement clothing: the limits of health promotion research. Can J Public Health (1992) 1.40
Oral health, dental prophylaxis and catheter related bloodstream infections in home parenteral nutrition patients: results of a UK survey and cohort study. Br Dent J (2012) 1.39
Antibiotic prophylaxis in dentistry: part II. A qualitative study of patient perspectives and understanding of the NICE guideline. Br Dent J (2011) 1.39
Air in the portal vein: sonographic and Doppler manifestations. Radiology (1991) 1.33
The free heavy chain of vertebrate skeletal myosin subfragment 1 shows full enzymatic activity. J Biol Chem (1982) 1.33
Fatal necrotizing esophagitis due to Penicillium chrysogenum in a patient with acquired immunodeficiency syndrome. Eur J Clin Microbiol Infect Dis (1992) 1.31
Small bowel biopsy for malabsorption: comparison of the diagnostic adequacy of endoscopic forceps and capsule biopsy specimens. Br Med J (Clin Res Ed) (1985) 1.30
Transposon-specified site-specific recombination. Proc Natl Acad Sci U S A (1982) 1.28
Carcinoid tumours of the rectum and anus. Br J Surg (1987) 1.27
The polymerase chain reaction in the demonstration of monoclonality in T cell lymphomas. J Clin Pathol (1995) 1.27
Spatial proximity of the two essential sulfhydryl groups of myosin. Biochemistry (1974) 1.26
Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain (2006) 1.23
Effect of nucleotide binding on the proximity of the essential sulfhydryl groups of myosin. Chemical probing of movement of residues during conformational transitions. Biochemistry (1977) 1.21
A typology of medical practice organization in Canada. Data from a national survey of physicians. Med Care (1990) 1.20
Nursing in genitourinary medicine: 10 years on from the Monks Report. The membership of GUNA. Genito-Urinary Nurses Association. Int J STD AIDS (1999) 1.19
Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. Br J Surg (1993) 1.17
Cooperative role of two sulfhydryl groups in myosin adenosine triphosphatase. Biochemistry (1974) 1.17
Home parenteral nutrition. Surg Gynecol Obstet (1979) 1.11
Studies on the "hinge" region of myosin. Biochemistry (1973) 1.11
False-negative dye-test findings in a case of fatal toxoplasmosis associated with cardiac transplantation. J Infect (1990) 1.11
Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax (1998) 1.11
Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis (2004) 1.10
Alzheimer's disease. New hope in the '90s. N C Med J (1994) 1.06
Cardiac rupture in patients with acute myocardial infarction. Chest (1987) 1.05
Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair. Tissue Eng (2005) 1.02
Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm (1992) 1.02
Can parathyroidectomy for primary hyperparathyroidism be carried out as a day-case procedure? J Laryngol Otol (2006) 1.01
The histopathology of splenic lymphoma with villous lymphocytes. Blood (1994) 1.01
Myosin adenosine triphosphatase. Convergence of activation by actin and by SH1 modification at physiological ionic strength. J Biol Chem (1974) 1.00
Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg (2002) 1.00
Crosslinking of myosin and myosin filaments. J Mechanochem Cell Motil (1973) 1.00
Effect of bridging the two essential thiols of myosin on its spectral and actin-binding properties. Biochemistry (1976) 0.99
High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol (1998) 0.99
Postseptal cellulitis: CT in diagnosis and management. Radiology (1986) 0.97
A comprehensive candidate gene study on bronchial asthma and juvenile idiopathic arthritis. Dis Markers (2006) 0.96
Fine needle aspiration biopsy in the diagnosis and management of fibroadenoma of the breast. Br J Surg (1990) 0.95
Geometry of the myosin dimer in high-salt media. I. Association behavior of rod segments from myosin. Biochemistry (1972) 0.95
Primary peritonitis due to group A streptococcus. J Clin Gastroenterol (2000) 0.95
Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur Respir J (1998) 0.95
Interobserver variation in the classification of thymic tumours--a multicentre study using the WHO classification system. Histopathology (2008) 0.94
Susceptibility-weighted angiography (SWAN) of cerebral veins and arteries compared to TOF-MRA. Eur J Radiol (2011) 0.93
Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant (2013) 0.93
Hospital treatment of acute poisoning. Lancet (1969) 0.93
Antibiotics for sore throat: impact of feedback to patients on the probability of bacterial infection. Ir Med J (2000) 0.92
Hypothermia to reduce neurological damage following coronary artery bypass surgery. Cochrane Database Syst Rev (2001) 0.92
Marital quality, depression, and inconsistent parenting: relationship with observed mother-child conflict. Am J Orthopsychiatry (1989) 0.92
Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat Med (1999) 0.91
Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? J Autoimmun (1990) 0.91
Chilling effect on mergers? Trustee (1990) 0.91
Smoking cessation among patients with head and neck cancer: cancer as a 'teachable moment'. Eur J Cancer Care (Engl) (2008) 0.91
Geometry of the myosin dimer in high-salt media. II. Hydrodynamic studies on macromodels of myosin and its rod segments. Biochemistry (1972) 0.90
How adequate are warnings and first and instructions on consumer product labels?: an investigation. Vet Hum Toxicol (1982) 0.90
Characteristics of established group practices in Ontario. Healthc Manage Forum (1989) 0.90
Studies of the agonist and antagonist activity of cicloprolol in man. Eur J Clin Pharmacol (1988) 0.89
Influences on breast feeding initiation and duration. Ir J Med Sci (1996) 0.89
Luekemic infiltration of the prostate: a case study and clinicopathological review. Cancer (1976) 0.89
Graft vessel disease and obliterative bronchiolitis after heart/lung transplantation in children. Transplant Proc (1995) 0.89
Letter: Poisoned children. Br Med J (1974) 0.89
Identification of myosin III as a protein kinase. Biochemistry (1996) 0.89
Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax (1998) 0.88
Cardiac size and VO2max do not decrease after short-term exercise cessation. Med Sci Sports Exerc (1986) 0.88
A controlled trial of the impact of the family practice nurse on volume, quality, and cost of rural health services. Med Care (1977) 0.88
Neuromodulatory role of acetylcholine in visually-induced cortical activation: behavioral and neuroanatomical correlates. Neuroscience (2008) 0.88
Cessation of cell proliferation by adjustment of cell redox potential. J Theor Biol (2001) 0.87
Open access mammography. Lancet (1988) 0.87
Redox-regulated mechanism may account for zerumbone's ability to suppress cancer-cell proliferation. Carcinogenesis (2002) 0.87
Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry (2005) 0.87
Bronchiolitis obliterans organizing pneumonia: the clinical and radiological features of seven cases and a review of the literature. Clin Radiol (1992) 0.87
Behavioural, biochemical and histological effects of trimethyltin (TMT) induced brain damage in the rat. Neurochem Int (1992) 0.86
Gastric lavage in the treatment of poisoning. A regional study. Practitioner (1968) 0.86
Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem (1998) 0.86
Ramifications of a redox switch within a normal cell: its absence in a cancer cell. Free Radic Biol Med (2008) 0.85
Campylobacter colitis: differentiation from acute inflammatory bowel disease. J R Soc Med (1985) 0.85